Anupam Rasayan has posted a blockbuster performance for FY26, driven by aggressive expansion, new product commercialization, and strategic global acquisitions, cementing its position in the specialty chemicals and CDMO space.
The company reported total FY26 revenue of Rs. 23,836 million, a sharp 65% jump from Rs. 14,485 million in FY25. EBITDA, including other income, rose 32% year-on-year to Rs. 5,430 million, while maintaining a strong EBITDA margin of 23%. Profit after tax climbed to Rs. 2,222 million from Rs. 1,600 million in the previous fiscal year.
Despite softer quarterly profitability, the company closed the year with solid momentum.
Q4FY26 revenue rose 26% year-on-year to Rs. 6,392 million compared with Rs 5,057 million in the same quarter last year. EBITDA for the quarter stood at Rs. 1,407 million, down 6% year-on-year, with EBITDA margin at 22%. Profit after tax for the quarter came in at Rs. 560 million against Rs. 629 million in Q4FY25.
Commenting on the performance, Anand Desai, Managing Director, Anupam Rasayan, said, “We are pleased to share that FY26 has been a landmark year for Anupam Rasayan, marked by strong operational execution, strategic expansion, and continued progress toward building a globally integrated specialty chemicals and CDMO platform.
"During the year, the Company achieved its highest-ever annual sales and operating cash flow performance, reflecting robust business momentum, operational efficiency, and strong cash generation. Growth was driven by commercialization of new products, addition of new multinational customers, and expanding engagements across key business verticals.
"We continue to strengthen our presence in niche and complex chemistries where technical expertise and long qualification cycles create strong entry barriers and sustainable growth opportunities."
A key strategic milestone, he said, during the year was the successful acquisition of Jayhawk Fine Chemicals in the United States.
"Jayhawk delivered strong proforma revenue of US$ 95Mn, reinforcing the strategic value of the acquisition and strengthening our global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. The acquisition also enhances our access to regulated markets and innovator customers across North America.
"Additionally, we have signed a definitive agreement to acquire Bliss GVS Pharma which will further strengthen our pharmaceutical value chain capabilities and is expected to create meaningful synergies across CDMO capabilities, product portfolio, and customer relationships.
"Looking ahead, we remain well-positioned for the next phase of growth, supported by increasing contribution from Performance Materials and Pharma segment, a strong product pipeline, and expanding global customer engagements.”
The company’s twin acquisitions — Jayhawk Fine Chemicals in the US and the planned takeover of Bliss GVS Pharma — mark a decisive push to deepen its global manufacturing footprint and pharmaceutical capabilities.
Management indicated that rising contributions from the Performance Materials and Pharma businesses, along with a growing multinational customer base, are expected to drive the next leg of growth.
With record annual revenue, expanding global operations, and a strengthened CDMO platform, Anupam Rasayan is positioning itself as a major emerging force in the global specialty chemicals sector.
